Skip to main content

Table 1 Clinical features of study population

From: Evaluation of the role of B7-H3 haplotype in association with impaired B7-H3 expression and protection against type 1 diabetes in Chinese Han population

 

T1D

HC

P value*

Sample size, n

121

120

 

Age, years

28.5 (8–53)

29.4 (24–49)

0.75

Gender, female(n%)

71 (58.68%)

72 (60.00%)

0.83

Duration, years

7 (0–39)

–

 

Fasting venous blood glucose (mmol/L)

11.9 (3.99–22.31)

–

 

Cr (umol/L)

56.19 (26.00–314.00)

–

 

BUN (umol/L)

4.43 (1.40–21.50)

–

 

UA (umol/L)

275.68 (81.00–540.00)

–

 

ALT (IU/L)

28.90 (1.00–414.00)

–

 

AST (IU/L)

21.32 (6.00–137.00)

–

 

TC (mmol/L)

4.42 (0.81–10.91)

–

 

TG (mmol/L)

1.09 (0.21–5.97)

–

 

LDL (mmol/L)

2.63 (1.10–7.37)

–

 

HDL (mmol/L)

1.52 (0.71–2.82)

–

 

HbA1c (%)

9.07% (5.30–18.4%)

–

 

Fasting C-peptide 0 min (ng/ml)

1.62(< 0.01–35.00)

  

Fasting C-peptide 120 min (ng/ml)

0.59(< 0.01–2.27)

–

 

Anti-ICA positive(%)#

18 (28.57%)

–

 

Anti-GAD positive(%)#

25 (39.68%)

–

 

Anti-IAA positive(%)#

7 (11.11%)

–

 

Ketosis

51 (42.15%)

–

 

IFN-γ (pg/ml)

3.07 (0–19.30)

–

 

IL-6(pg/ml)

4.16 (0–15.63)

–

 

TNF-α (pg/ml)

1.46 (0–17.23)

–

 
  1. Cr for creatinine, BUN for blood urea nitrogen, UA for uric acid, ALT for alanine aminotransferase, AST for aspartate transferase, TC for cholesterol, TG for triglycerides, LDL for low-density lipoprotein, HDL for high-density lipoprotein, ICA for islet cell antibodies, GAD for glutamic acid decarboxylase antibody, IAA for insulin autoantibody. *P value is based on the statistical analysis by the Mann-Whitney U test or the χ2 test assessing overall group differences. #Not all the patients have the antibody results, only 63 patients received antibody screening